Mutational signatures in esophageal adenocarcinoma define etiologically distinct subgroups with therapeutic relevance

Nature Genetics

Volumn 48, Issue 10, 2016, Pages 1131-1141

  Secrier, Maria ^a   Li, Xiaodun ^b   De Silva, Nadeera ^b   Eldridge, Matthew D ^a   Contino, Gianmarco ^b   Bornschein, Jan ^b   Macrae, Shona ^b   Grehan, Nicola ^b   O'Donovan, Maria ^b,c   Miremadi, Ahmad ^b,c   Yang, Tsun Po ^b   Bower, Lawrence ^a   Chettouh, Hamza ^b   Crawte, Jason ^b   Galeano Dalmau, Núria ^b   Grabowska, Anna ^d   Saunders, John ^e   Underwood, Tim ^f,g   Waddell, Nicola ^h   Barbour, Andrew P ⁱ   Nutzinger, Barbara ^b   Achilleos, Achilleas ^a   Edwards, Paul A W ^j   Lynch, Andy G ^a   Tavaré, Simon ^a   Fitzgerald, Rebecca C ^b   Noorani, Ayesha ^b   Elliott, Rachael Fels ^b   Weaver, Jamie ^b   Ross Innes, Caryn ^b   Smith, Laura ^b   Abdullahi, Zarah ^b   De La Rue, Rachel ^b   Cluroe, Alison ^c   Malhotra, Shalini ^c   Hardwick, Richard ^m   Ford, Hugo ^k   Smith, Mike L ^a   Davies, Jim ^l   Turkington, Richard ^m   Hayes, Stephen J ^n,o   Ang, Yeng ^n,p,q   Preston, Shaun R ^r   Oakes, Sarah ^r   Bagwan, Izhar ^r   Save, Vicki ^s   Skipworth, Richard J E ^s   Hupp, Ted R ^s   O'Neill, J Robert ^s,t   Tucker, Olga ^u,v   Taniere, Philippe ^u   Noble, Fergus ^g   Owsley, Jack ^g   Lovat, Laurence ^w   Haidry, Rehan ^w   Eneh, Victor ^w   Crichton, Charles ^l   Barr, Hugh ^x   Shepherd, Neil ^x   Old, Oliver ^x   Lagergren, Jesper ^y,z,aa   Gossage, James ^y,z   Davies, Andrew ^y,z   Chang, Fuju ^y,z   Zylstra, Janine ^y,z   Sanders, Grant ^ab   Berrisford, Richard ^ab   Harden, Catherine ^ab   Bunting, David ^ab   Lewis, Mike ^ac   Cheong, Ed ^ac   Kumar, Bhaskar ^ac   Parsons, Simon L ^e   Soomro, Irshad ^e   Kaye, Philip ^e   Collier, Pamela ^e   Igali, Laszlo ^ad   Welch, Ian ^ae   Scott, Michael ^ae   Sothi, Shamila ^af   Suortamo, Sari ^af   Lishman, Suzy ^ag   Beardsmore, Duncan ^ah   Francies, Hayley E ^ai   Garnett, Mathew J ^ai   Pearson, John V ^h,i   Nones, Katia ^h,i   Patch, Ann Marie ^h,i   Grimmond, Sean M ^i,aj   more..

^a CANCER RESEARCH UK CAMBRIDGE RESEARCH INSTITUTE   (United Kingdom)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^c CAMBRIDGE UNIVERSITY HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

^d UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^e NOTTINGHAM UNIVERSITY HOSPITALS NHS TRUST   (United Kingdom)

^f UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^g UNIVERSITY HOSPITAL SOUTHAMPTON NHS FOUNDATION TRUST   (United Kingdom)

^h QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE   (Australia)

ⁱ UNIVERSITY OF QUEENSLAND   (Australia)

^j UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^k ADDENBROOKE S HOSPITAL   (United Kingdom)

^l UNIVERSITY OF OXFORD   (United Kingdom)

^m QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

ⁿ SALFORD ROYAL NHS FOUNDATION TRUST   (United Kingdom)

^o UNIVERSITY OF MANCHESTER   (United Kingdom)

^p Wrightington Wigan and Leigh NHS Trust   (United Kingdom)

^q UNIVERSITY OF MANCHESTER   (United Kingdom)

^r ROYAL SURREY COUNTY HOSPITAL   (United Kingdom)

^s ROYAL INFIRMARY OF EDINBURGH   (United Kingdom)

^t UNIVERSITY OF EDINBURGH   (United Kingdom)

^u UNIVERSITY HOSPITALS BIRMINGHAM NHS FOUNDATION TRUST   (United Kingdom)

^v UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^w UNIVERSITY COLLEGE LONDON   (United Kingdom)

^x GLOUCESTERSHIRE ROYAL HOSPITAL   (United Kingdom)

^y ST THOMAS HOSPITAL   (United Kingdom)

^z KING'S COLLEGE LONDON   (United Kingdom)

^aa KAROLINSKA INSTITUTE   (Sweden)

^ab PLYMOUTH HOSPITALS NHS TRUST   (United Kingdom)

^ac NORFOLK AND NORWICH UNIVERSITY HOSPITAL   (United Kingdom)

^ad Norfolk and Waveney Cellular Pathology Network   (United Kingdom)

^ae MANCHESTER UNIVERSITY NHS FOUNDATION TRUST   (United Kingdom)

^af UNIVERSITY HOSPITALS COVENTRY AND WARWICKSHIRE NHS TRUST   (United Kingdom)

^ag PETERBOROUGH CITY HOSPITAL   (United Kingdom)

^ah UNIVERSITY HOSPITAL OF NORTH STAFFORDSHIRE   (United Kingdom)

^ai WELLCOME TRUST SANGER INSTITUTE   (United Kingdom)

^aj UNIVERSITY OF MELBOURNE   (Australia)

more..

Author keywords

[No Author keywords available]

Indexed keywords

2 ALLYL 1 [6 (1 HYDROXY 1 METHYLETHYL) 2 PYRIDINYL] 6 [4 (4 METHYL 1 PIPERAZINYL)ANILINO] 1H PYRAZOLO[3,4 D]PYRIMIDIN 3(2H) ONE; 5 (3 FLUOROPHENYL) N (3 PIPERIDINYL) 3 UREIDO 2 THIOPHENECARBOXAMIDE; AZD 4547; CD8 ANTIGEN; CRIZOTINIB; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; LAPATINIB; MITOGEN ACTIVATED PROTEIN KINASE; OLAPARIB; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN MDM2; PROTEIN TYROSINE KINASE; TRANSCRIPTION FACTOR GATA 4; TRANSCRIPTION FACTOR GATA 6; TUMOR ANTIGEN; ANTINEOPLASTIC AGENT; DNA; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR;

ARTICLE; CANCER GENETICS; CELL CYCLE; CHROMATIN ASSEMBLY AND DISASSEMBLY; CONTROLLED STUDY; DNA DAMAGE RESPONSE; DNA FLANKING REGION; DNA REPAIR; DOMINANT GENE; ESOPHAGEAL ADENOCARCINOMA; EXOME; GENE ACTIVATION; GENE AMPLIFICATION; GENE DOSAGE; GENE FREQUENCY; GENE MUTATION; GENE SEQUENCE; GENE TARGETING; GENETIC ASSOCIATION; GENOME ANALYSIS; HETEROZYGOSITY LOSS; HOMOLOGOUS RECOMBINATION; HUMAN; HUMAN CELL; IN VITRO STUDY; INDEL MUTATION; MICROSATELLITE INSTABILITY; MITOGENICITY; MOLECULAR GENETICS; MUTATIONAL LOAD; POINT MUTATION; PRIMARY CELL LINE; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; TREATMENT RESPONSE; TUMOR CLASSIFICATION; ADENOCARCINOMA; AGED; ANTAGONISTS AND INHIBITORS; CLASSIFICATION; COHORT ANALYSIS; DNA DAMAGE; DNA SEQUENCE; ESOPHAGEAL NEOPLASMS; FEMALE; GENETIC HETEROGENEITY; GENETICS; HUMAN GENOME; IMMUNOLOGY; MALE; METABOLISM; MUTATION; TUMOR CELL LINE;

ADENOCARCINOMA; AGED; ANTIGENS, CD8; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; COHORT STUDIES; DNA DAMAGE; DNA, NEOPLASM; ESOPHAGEAL NEOPLASMS; FEMALE; GENETIC HETEROGENEITY; GENOME, HUMAN; HUMANS; MALE; MUTATION; POLY(ADP-RIBOSE) POLYMERASE INHIBITORS; RECEPTOR PROTEIN-TYROSINE KINASES; SEQUENCE ANALYSIS, DNA;

EID: 84987629410     PISSN: 10614036     EISSN: 15461718     Source Type: Journal    
DOI: 10.1038/ng.3659     Document Type: Article

References (83)

1. Ferlay, J. et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int. J. Cancer 136, E359-E386 (2015).
2. Brown, L. M., Devesa, S. S. & Chow, W. H. Incidence of adenocarcinoma of the esophagus among white Americans by sex, stage, and age. J. Natl. Cancer Inst. 100, 1184-1187 (2008).
3. Cunningham, D., Okines, A. F. & Ashley, S. Capecitabine and oxaliplatin for advanced esophagogastric cancer. N. Engl. J. Med. 362, 858-859 (2010).
4. Allum, W. H., Stenning, S. P., Bancewicz, J., Clark, P. I. & Langley, R. E. Long-term results of a randomized trial of surgery with or without preoperative chemotherapy in esophageal cancer. J. Clin. Oncol. 27, 5062-5067 (2009).
5. Cunningham, D. et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N. Engl. J. Med. 355, 11-20 (2006).
6. van Hagen, P. et al. Preoperative chemoradiotherapy for esophageal or junctional cancer. N. Engl. J. Med. 366, 2074-2084 (2012).
7. Bang, Y. J. et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 376, 687-697 (2010).
8. Gao, Y. B. et al. Genetic landscape of esophageal squamous cell carcinoma. Nat. Genet. 46, 1097-1102 (2014).
9. Schulze, K. et al. Exome sequencing of hepatocellular carcinomas identifies new mutational signatures and potential therapeutic targets. Nat. Genet. 47, 505-511 (2015).
10. Cancer Genome Atlas Network. Genomic classification of cutaneous melanoma. Cell 161, 1681-1696 (2015).
11. Waddell, N. et al. Whole genomes redefine the mutational landscape of pancreatic cancer. Nature 518, 495-501 (2015).
12. Totoki, Y. et al. Trans-ancestry mutational landscape of hepatocellular carcinoma genomes. Nat. Genet. 46, 1267-1273 (2014).
13. Cancer Genome Atlas Research Network. Comprehensive molecular characterization of gastric adenocarcinoma. Nature 513, 202-209 (2014).
14. Cancer Genome Atlas Research Network. Comprehensive molecular profiling of lung adenocarcinoma. Nature 511, 543-550 (2014).
15. Chantrill, L. A. et al. Precision medicine for advanced pancreas cancer: The Individualized Molecular Pancreatic Cancer Therapy (IMPaCT) Trial. Clin. Cancer Res. 21, 2029-2037 (2015).
16. Dulak, A. M. et al. Exome and whole-genome sequencing of esophageal adenocarcinoma identifies recurrent driver events and mutational complexity. Nat. Genet. 45, 478-486 (2013).
17. Weaver, J. M. et al. Ordering of mutations in preinvasive disease stages of esophageal carcinogenesis. Nat. Genet. 46, 837-843 (2014).
18. Nones, K. et al. Genomic catastrophes frequently arise in esophageal adenocarcinoma and drive tumorigenesis. Nat. Commun. 5, 5224 (2014).
19. Cancer Genome Atlas Research Network. et al. The Cancer Genome Atlas Pan-Cancer analysis project. Nat. Genet. 45, 1113-1120 (2013).
20. Paterson, A. L. et al. Mobile element insertions are frequent in oesophageal adenocarcinomas and can mislead paired-end sequencing analysis. BMC Genomics 16, 473 (2015).
21. Tubio, J. M. et al. Mobile DNA in cancer. Extensive transduction of nonrepetitive DNA mediated by L1 retrotransposition in cancer genomes. Science 345, 1251343 (2014).
22. Mermel, C. H. et al. GISTIC2. 0 facilitates sensitive and confident localization of the targets of focal somatic copy-number alteration in human cancers. Genome Biol. 12, R41 (2011).
23. Lawrence, M. S. et al. Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature 499, 214-218 (2013).
24. Nik-Zainal, S. et al. The life history of 21 breast cancers. Cell 149, 994-1007 (2012).
25. Paterson, A. L. et al. Characterization of the timing and prevalence of receptor tyrosine kinase expression changes in oesophageal carcinogenesis. J. Pathol. 230, 118-128 (2013).
26. Van Cutsem, E. et al. HER2 screening data from ToGA: targeting HER2 in gastric and gastroesophageal junction cancer. Gastric Cancer 18, 476-484 (2015).
27. Alexandrov, L. B. et al. Signatures of mutational processes in human cancer. Nature 500, 415-421 (2013).
28. Shiraishi, Y., Tremmel, G., Miyano, S. & Stephens, M. A simple model-based approach to inferring and visualizing cancer mutation signatures. PLoS Genet. 11, e1005657 (2015).
29. Gehring, J. S., Fischer, B., Lawrence, M. & Huber, W. SomaticSignatures: inferring mutational signatures from single-nucleotide variants. Bioinformatics 31, 3673-3675 (2015).
30. Pearl, L. H., Schierz, A. C., Ward, S. E., Al-Lazikani, B. & Pearl, F. M. Therapeutic opportunities within the DNA damage response. Nat. Rev. Cancer 15, 166-180 (2015).
31. Shen, J. et al. ARID1A deficiency impairs the DNA damage checkpoint and sensitizes cells to PARP inhibitors. Cancer Discov. 5, 752-767 (2015).
32. Hodi, F. S. et al. Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 363, 711-723 (2010).
33. Larkin, J. et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N. Engl. J. Med. 373, 23-34 (2015).
34. Herbst, R. S. et al. Pembrolizumab versus docetaxel for previously treated, PDL1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet 387, 1540-1550 (2016).
35. Rizvi, N. A. et al. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science 348, 124-128 (2015).
36. Snyder, A. et al. Genetic basis for clinical response to CTLA-4 blockade in melanoma. N. Engl. J. Med. 371, 2189-2199 (2014).
37. McGranahan, N. et al. Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade. Science 351, 1463-1469 (2016).
38. Van Allen, E. M. et al. Genomic correlates of response to CTLA-4 blockade in metastatic melanoma. Science 350, 207-211 (2015).
39. Tumeh, P. C. et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature 515, 568-571 (2014).
40. Hamanishi, J. et al. Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer. Proc. Natl. Acad. Sci. USA 104, 3360-3365 (2007).
41. Benafif, S. & Hall, M. An update on PARP inhibitors for the treatment of cancer. Onco Targets Ther. 8, 519-528 (2015).
42. Oza, A. M. et al. Olaparib combined with chemotherapy for recurrent platinumsensitive ovarian cancer: a randomised phase 2 trial. Lancet Oncol. 16, 87-97 (2015).
43. Demel, H. R. et al. Effects of topoisomerase inhibitors that induce DNA damage response on glucose metabolism and PI3K/Akt/mTOR signaling in multiple myeloma cells. Am. J. Cancer Res. 5, 1649-1664 (2015).
44. Farmer, H. et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 434, 917-921 (2005).
45. Di Leonardo, A., Linke, S. P., Clarkin, K. & Wahl, G. M. DNA damage triggers a prolonged p53-dependent G1 arrest and long-term induction of Cip1 in normal human fibroblasts. Genes Dev. 8, 2540-2551 (1994).
46. Agarwal, M. L. et al. A p53-dependent S-phase checkpoint helps to protect cells from DNA damage in response to starvation for pyrimidine nucleotides. Proc. Natl. Acad. Sci. USA 95, 14775-14780 (1998).
47. Brooks, K. et al. A potent Chk1 inhibitor is selectively cytotoxic in melanomas with high levels of replicative stress. Oncogene 32, 788-796 (2013).
48. Vera, J. et al. Chk1 and Wee1 control genotoxic-stress induced G2-M arrest in melanoma cells. Cell. Signal. 27, 951-960 (2015).
49. Liu, Q. et al. Chk1 is an essential kinase that is regulated by Atr and required for the G2/M DNA damage checkpoint. Genes Dev. 14, 1448-1459 (2000).
50. Watanabe, N., Broome, M. & Hunter, T. Regulation of the human WEE1Hu CDK tyrosine 15-kinase during the cell cycle. EMBO J. 14, 1878-1891 (1995).
51. van de Wetering, M. et al. Prospective derivation of a living organoid biobank of colorectal cancer patients. Cell 161, 933-945 (2015).
52. Sato, T. et al. Single Lgr5 stem cells build crypt-villus structures in vitro without a mesenchymal niche. Nature 459, 262-265 (2009).
53. Ciriello, G. et al. Emerging landscape of oncogenic signatures across human cancers. Nat. Genet. 45, 1127-1133 (2013).
54. Osato, M. Point mutations in the RUNX1/AML1 gene: another actor in RUNX leukemia. Oncogene 23, 4284-4296 (2004).
55. Watkins, J. A., Irshad, S., Grigoriadis, A. & Tutt, A. N. Genomic scars as biomarkers of homologous recombination deficiency and drug response in breast and ovarian cancers. Breast Cancer Res. 16, 211 (2014).
56. Alexandrov, L. B., Nik-Zainal, S., Siu, H. C., Leung, S. Y. & Stratton, M. R. A mutational signature in gastric cancer suggests therapeutic strategies. Nat. Commun. 6, 8683 (2015).
57. Ledermann, J. et al. Olaparib maintenance therapy in patients with platinumsensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial. Lancet Oncol. 15, 852-861 (2014).
58. Verhagen, C. V. et al. Extent of radiosensitization by the PARP inhibitor olaparib depends on its dose, the radiation dose and the integrity of the homologous recombination pathway of tumor cells. Radiother. Oncol. 116, 358-365 (2015).
59. Kelly, R. J. et al. Adaptive immune resistance in gastro-esophageal cancer: correlating tumoral/stromal PDL1 expression with CD8+ cell count. J. Clin. Oncol. 33, abstr. 4031 (2015).
60. Nakamura, H. et al. Genomic spectra of biliary tract cancer. Nat. Genet. 47, 1003-1010 (2015).
61. Bridges, K. A. et al. MK-1775, a novel Wee1 kinase inhibitor, radiosensitizes p53-defective human tumor cells. Clin. Cancer Res. 17, 5638-5648 (2011).
62. Wang, Y. et al. Radiosensitization of p53 mutant cells by PD0166285, a novel G2 checkpoint abrogator. Cancer Res. 61, 8211-8217 (2001).
63. Liu, D. S. et al. APR-246 potently inhibits tumour growth and overcomes chemoresistance in preclinical models of oesophageal adenocarcinoma. Gut 64, 1506-1516 (2015).
64. Stewart, A., Thavasu, P., de Bono, J. S. & Banerji, U. Titration of signalling output: insights into clinical combinations of MEK and AKT inhibitors. Ann. Oncol. 26, 1504-1510 (2015).
65. Li, H. & Durbin, R. Fast and accurate short read alignment with Burrows-Wheeler transform. Bioinformatics 25, 1754-1760 (2009).
66. Saunders, C. T. et al. Strelka: accurate somatic small-variant calling from sequenced tumor-normal sample pairs. Bioinformatics 28, 1811-1817 (2012).
67. McLaren, W. et al. Deriving the consequences of genomic variants with the Ensembl API and SNP Effect Predictor. Bioinformatics 26, 2069-2070 (2010).
68. Van Loo, P. et al. Allele-specific copy number analysis of tumors. Proc. Natl. Acad. Sci. USA 107, 16910-16915 (2010).
69. McKenna, A. et al. The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. Genome Res. 20, 1297-1303 (2010).
70. Zack, T. I. et al. Pan-cancer patterns of somatic copy number alteration. Nat. Genet. 45, 1134-1140 (2013).
71. Boeva, V. et al. Control-FREEC: a tool for assessing copy number and allelic content using next-generation sequencing data. Bioinformatics 28, 423-425 (2012).
72. Chen, X. et al. Manta: rapid detection of structural variants and indels for germline and cancer sequencing applications. Bioinformatics 32, 1220-1222 (2016).
73. Schulte, I. et al. Structural analysis of the genome of breast cancer cell line ZR-75-30 identifies twelve expressed fusion genes. BMC Genomics 13, 719 (2012).
74. Le Tallec, B. et al. Common fragile site profiling in epithelial and erythroid cells reveals that most recurrent cancer deletions lie in fragile sites hosting large genes. Cell Reports 4, 420-428 (2013).
75. Auton, A. et al. A global reference for human genetic variation. Nature 526, 68-74 (2015).
76. Wilkerson, M. D. & Hayes, D. N. ConsensusClusterPlus: a class discovery tool with confidence assessments and item tracking. Bioinformatics 26, 1572-1573 (2010).
77. Nilsen, G. et al. Copynumber: efficient algorithms for single-and multi-track copy number segmentation. BMC Genomics 13, 591 (2012).
78. Korbel, J. O. & Campbell, P. J. Criteria for inference of chromothripsis in cancer genomes. Cell 152, 1226-1236 (2013).
79. Puente, X. S. et al. Non-coding recurrent mutations in chronic lymphocytic leukaemia. Nature 526, 519-524 (2015).
80. Kumar, P., Henikoff, S. & Ng, P. C. Predicting the effects of coding non-synonymous variants on protein function using the SIFT algorithm. Nat. Protoc. 4, 1073-1081 (2009).
81. Adzhubei, I. A. et al. A method and server for predicting damaging missense mutations. Nat. Methods 7, 248-249 (2010).
82. Lundegaard, C. et al. NetMHC-3. 0: accurate web accessible predictions of human, mouse and monkey MHC class I affinities for peptides of length 8-11. Nucleic Acids Res. 36, W509-W512 (2008).
83. Adiconis, X. et al. Comparative analysis of RNA sequencing methods for degraded or low-input samples. Nat. Methods 10, 623-629 (2013).